InvestorsHub Logo
Followers 467
Posts 26918
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 66

Monday, 05/07/2012 9:08:55 AM

Monday, May 07, 2012 9:08:55 AM

Post# of 69
8:35AM Ardea Biosciences misses on top and bottom lines (RDEA) 31.70 : Reports net loss of $1.25 per share vs ($1.01) CIQ est; revs decreased 17% YoY to $1.5 mln vs $1.9 mln CIQ est. Co states the decrease in revenues in 2012 as compared to 2011 was primarily due to a decrease in reimbursable research and development costs related to BAY86-9766, which are reimbursed under the terms of our global license agreement with Bayer HealthCare (BAYRY)